doi: 10.1016/j.cmet.2019.07.013 138 ZhangQDelessaCTAugustinRBakhtiMColldnGDruckerDJet al
For example, a recent analysis of the FDAs reporting system (FAERS) highlighted that taste disturbances (dysgeusia) are noted more frequently by patients using GLP-1RAs in everyday practice than in clinical trial reports (161)
Consider reducing your fiber dose by 50% on injection day and the day after, particularly during the first 4 to 8 weeks of treatment or after dose increases
A recent study found that semaglutide drugs, including Ozempic and Wegovy, may increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss
The evolving strategy comes as fast-food chains brace for what could become one of the industrys biggest long-term challenges
There is no objective measurement of GLP-1 levels or body composition changes